GoAI
Get started
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc.

ELVN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$59.82

+$0.90 · +1.53%

Aug 21, 4:00 PM ET

ELVN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

40

Expensive

Momentum

63

Gaining

Sentiment

61

Bullish

Risk resilience

67

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Richard A. Fair
Listed since
Mar 12, 2020
Employees
67

Market position

Day range

Current $59.82

52-week range

Current $59.82

Open
$58.98
Previous close
$58.92
Volume
596.37K
0.5× average
Average volume
1.2M
Average daily volume
Market cap
4.27B USD
Beta
0.24
Market reference 1
50-day average
$52.8208
+13.25% above average
200-day average
$35.639
+67.85% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
774.13M USD
P/E (TTM)
-36.48×
P/B (TTM)
4.42×
P/S (TTM)
0×
EV / EBITDA
-7.48×
Earnings yield
-11.88%
Free cash flow yield
-8.07%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-22.56%
Return on assets
-21.78%
Return on invested capital
-26.01%

Financial health

Debt / equity
0×
Current ratio
28.66×
Altman Z-score
170.27
Piotroski F-score
2 of 9

Financial statements

Income trends

Operating income

−119.66M USD-14.45%

Net income

−103.69M USD-16.48%
Income trends across reported periods−15.25M USD−53.22M USD−91.18M USD−129.15M USDOperating income, FY2021: −24.76M USDOperating income, FY2022: −38.79M USDOperating income, FY2023: −83.53M USDOperating income, FY2024: −104.55M USDOperating income, FY2025: −119.66M USDNet income, FY2021: −24.74M USDNet income, FY2022: −37.66M USDNet income, FY2023: −71.58M USDNet income, FY2024: −89.02M USDNet income, FY2025: −103.69M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −24.76M USD. Operating income FY2022 −38.79M USD. Operating income FY2023 −83.53M USD. Operating income FY2024 −104.55M USD. Operating income FY2025 −119.66M USD. Net income FY2021 −24.74M USD. Net income FY2022 −37.66M USD. Net income FY2023 −71.58M USD. Net income FY2024 −89.02M USD. Net income FY2025 −103.69M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold263K USD————
Gross profit−263K USD————
Research and development85.86M USD80.78M USD64.57M USD31.02M USD20.47M USD
Selling, general, and administrative33.8M USD23.78M USD18.96M USD7.77M USD4.29M USD
Operating expenses119.4M USD104.55M USD83.53M USD38.79M USD24.76M USD
Interest income16.01M USD14.89M USD11.97M USD1.13M USD22K USD
Depreciation and amortization263K USD317K USD297K USD215K USD115K USD
Operating income−119.66M USD−104.55M USD−83.53M USD−38.79M USD−24.76M USD
Net income−103.69M USD−89.02M USD−71.58M USD−37.66M USD−24.74M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+6.12%
11 comparable reports
Latest EPS result
-0.49
Estimate -0.39 · Miss by 26.56%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.28-0.39-0.5-0.61Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual -0.46, estimate -0.53, surprise +13.21%, Beat. Q2 2025, reported May 14, 2025: actual -0.57, estimate -0.51, surprise -11.76%, Miss. Q3 2025, reported Aug 13, 2025: actual -0.49, estimate -0.53, surprise +7.55%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.32, estimate -0.43, surprise +25.58%, Beat. Q1 2026, reported Mar 3, 2026: actual -0.48, estimate -0.42, surprise -14.29%, Miss. Q2 2026, reported May 7, 2026: actual -0.38, estimate -0.44, surprise +13.64%, Beat. Q3 2026, reported Aug 5, 2026: actual -0.49, estimate -0.387, surprise -26.56%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.43, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates474.53K318.72K162.9K7.08KQ1 '24No estimateQ4 '25EstimateQ1 '26Estimate
Q1 2024, reported Mar 14, 2024: actual 440K USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 12, 2025: actual —, estimate 8.33K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 3, 2026: actual —, estimate 12.5K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$76.00

27.05% upside
Past 12 months12-month forecastHigh $82.00Average $76.00Low $65.00

Corporate actions

Corporate action history

Stock split

Effective Feb 24, 2023

1:4

ELVN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ELVN

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
64.82M
Weight
0.08%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
24.47M
Weight
0.23%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
23.47M
Weight
0.16%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
15.31M
Weight
0.07%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
13.17M
Weight
0.07%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
State Street SPDR S&P Pharmaceuticals ETF logoState Street SPDR S&P Pharmaceuticals ETFXPH
Market value
12.71M
Weight
2.27%
AUM
560.87M USD
Expense ratio
0.35%
Price / 1D
$72.80+0.71%
iShares U.S. Pharmaceuticals ETF logoiShares U.S. Pharmaceuticals ETFIHE
Market value
11.83M
Weight
0.69%
AUM
1.74B USD
Expense ratio
0.37%
Price / 1D
$106.79+1.01%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
10.23M
Weight
0.06%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%

Continue in GoAI

Research ELVN

research.disclaimer